BOLD: Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse

Imfinzi (durvalumab) - AstraZeneca

Equidacent (bevacizumab biosimilar) - Fujifilm Kyowa Kirin Biologics, AstraZeneca, Centus Biotherap

Lynparza (olaparib) - Merck (MSD), AstraZeneca

http://clinicaltrials.gov/ct2/show/NCT04015739

Dec 7, 2021